This report surveys the world literature concerning prognostic variables for patients with esthesioneuroblastoma, an uncommon tumor arising from the olfactory epithelium. Specific sites of local and regional tumor extension, recurrence of disease after treatment, distant metastasis, and patient age were all found to be related to patient prognosis. There is a higher cure rate for patients treated after 1966, indicating an improvement in treatment methods. Also, the results indicate that in more recent years patients are being diagnosed and treated with less advanced disease. A statistical procedure, discriminant analysis, was employed, which permits the oncologist to predict patient outcome accurately. The discriminant function equation was 87% correct in identifying patients with tumor control (for a minimum period of 36 months) or recurrence and was 84% correct in classifying patients free of disease for at least 60 months or with recurrence. The statistical procedures employed in this report can be extended to other tumors and survival criteria.

Download full-text PDF

Source
http://dx.doi.org/10.1002/1097-0142(19801201)46:11<2509::aid-cncr2820461132>3.0.co;2-zDOI Listing

Publication Analysis

Top Keywords

tumor control
8
months recurrence
8
patients
5
olfactory esthesioneuroblastoma--variables
4
esthesioneuroblastoma--variables predictive
4
tumor
4
predictive tumor
4
recurrence
4
control recurrence
4
recurrence report
4

Similar Publications

Deciphering the complex clonal heterogeneity of polycythemia vera and the response to interferon alpha.

Blood Adv

January 2025

Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany.

Interferon alpha (IFNa) is approved for the therapy of patients (pts) with polycythemia vera (PV), a subtype of myeloproliferative neoplasms (MPN). Some pts achieve molecular responses (MR), but clonal factors sensitizing for MR remain elusive. We integrated colony formation and differentiation assays with single-cell RNA seq and genotyping in PV-derived cells vs.

View Article and Find Full Text PDF

Coding Variants of the Genitourinary Development Gene Carry High Risk for Prostate Cancer.

JCO Precis Oncol

January 2025

Medical Research Service, Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, TN.

Purpose: Considerable genetic heterogeneity is currently thought to underlie hereditary prostate cancer (HPC). Most families meeting criteria for HPC cannot be attributed to currently known pathogenic variants.

Methods: To discover pathogenic variants predisposing to prostate cancer, we conducted a familial case-control association study using both genome-wide single-allele and identity-by-descent analytic approaches.

View Article and Find Full Text PDF

Oral Microalgae-Based Biosystem to Enhance Irreversible Electroporation Immunotherapy in Hepatocellular Carcinoma.

Adv Sci (Weinh)

January 2025

Department of Surgery, Center for Cancer Medicine, the Fourth Affiliated Hospital of School of Medicine, International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.

Irreversible electroporation (IRE) is a novel local tumor ablation technique that can potentially stimulate immune responses. However, IRE alone cannot effectively activate the immune system or prevent distant metastases. Therefore, this study utilized the biocompatibility of Chlorella vulgaris (C.

View Article and Find Full Text PDF

Objective: The case-control study aims to identify the potential risk and protective factors contributing to breast cancer risk in the high-incidence Aizawl population and the low-incidence Agartala population, using age-specific prevalence data of established reproductive factors and body mass index (BMI) among healthy women.

Methods: A risk profile survey was conducted on asymptomatic women aged 30-64 in Aizawl and Agartala towns. Data was analysed using SPSS software.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!